DBVT Quote, Financials, Valuation and Earnings

Akari Therapeutics PLC has a net margin of -- compared to DBV Technologies SA's net margin of --. DBV Technologies SA's return on equity of -- beat Akari Therapeutics PLC's return on equity of --.

DBV Technologies SA has a consensus price target of $16.06, signalling upside risk potential of 64.81%. On the other hand Akari Therapeutics PLC has an analysts' consensus of $7.00 which suggests that it could grow by 530.63%. Given that Akari Therapeutics PLC has higher upside potential than DBV Technologies SA, analysts believe Akari Therapeutics PLC is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of -0.587, which suggesting that the stock is 158.693% less volatile than S&P 500. In comparison Akari Therapeutics PLC has a beta of 0.211, suggesting its less volatile than the S&P 500 by 78.884%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akari Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Akari Therapeutics PLC pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Akari Therapeutics PLC quarterly revenues of --. DBV Technologies SA's net income of -$27.1M is lower than Akari Therapeutics PLC's net income of -$3.7M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Akari Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus -- for Akari Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.

Cellectis SA has a net margin of -- compared to DBV Technologies SA's net margin of -170.14%. DBV Technologies SA's return on equity of -- beat Cellectis SA's return on equity of -49.15%.

DBV Technologies SA has a consensus price target of $16.06, signalling upside risk potential of 64.81%. On the other hand Cellectis SA has an analysts' consensus of $5.75 which suggests that it could grow by 188.95%. Given that Cellectis SA has higher upside potential than DBV Technologies SA, analysts believe Cellectis SA is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of -0.587, which suggesting that the stock is 158.693% less volatile than S&P 500. In comparison Cellectis SA has a beta of 2.910, suggesting its more volatile than the S&P 500 by 191%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cellectis SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Cellectis SA pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Cellectis SA quarterly revenues of $10.7M. DBV Technologies SA's net income of -$27.1M is lower than Cellectis SA's net income of -$18.1M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Cellectis SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 4.08x for Cellectis SA. Usually stocks with elevated PS ratios are considered overvalued.

Edap TMS SA has a net margin of -- compared to DBV Technologies SA's net margin of -52.18%. DBV Technologies SA's return on equity of -- beat Edap TMS SA's return on equity of -49.1%.

DBV Technologies SA has a consensus price target of $16.06, signalling upside risk potential of 64.81%. On the other hand Edap TMS SA has an analysts' consensus of $5.75 which suggests that it could grow by 291.16%. Given that Edap TMS SA has higher upside potential than DBV Technologies SA, analysts believe Edap TMS SA is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of -0.587, which suggesting that the stock is 158.693% less volatile than S&P 500. In comparison Edap TMS SA has a beta of -0.003, suggesting its less volatile than the S&P 500 by 100.255%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Edap TMS SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Edap TMS SA pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Edap TMS SA quarterly revenues of $14.3M. DBV Technologies SA's net income of -$27.1M is lower than Edap TMS SA's net income of -$7.4M. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Edap TMS SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 0.82x for Edap TMS SA. Usually stocks with elevated PS ratios are considered overvalued.

Genfit SA has a net margin of -- compared to DBV Technologies SA's net margin of --. DBV Technologies SA's return on equity of -- beat Genfit SA's return on equity of --.

DBV Technologies SA has a consensus price target of $16.06, signalling upside risk potential of 64.81%. On the other hand Genfit SA has an analysts' consensus of $8.70 which suggests that it could grow by 126.92%. Given that Genfit SA has higher upside potential than DBV Technologies SA, analysts believe Genfit SA is more attractive than DBV Technologies SA.

DBV Technologies SA has a beta of -0.587, which suggesting that the stock is 158.693% less volatile than S&P 500. In comparison Genfit SA has a beta of 1.082, suggesting its more volatile than the S&P 500 by 8.244%.

DBV Technologies SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Genfit SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. DBV Technologies SA pays -- of its earnings as a dividend. Genfit SA pays out -- of its earnings as a dividend.

DBV Technologies SA quarterly revenues are --, which are smaller than Genfit SA quarterly revenues of --. DBV Technologies SA's net income of -$27.1M is higher than Genfit SA's net income of --. Notably, DBV Technologies SA's price-to-earnings ratio is -- while Genfit SA's PE ratio is 32.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for DBV Technologies SA is -- versus 2.66x for Genfit SA. Usually stocks with elevated PS ratios are considered overvalued.